Generate Biomedicines Expands Leadership Team with the Addition of Chief Medical Officer Alexandra Snyder, M.D.
- S&P 500, Nasdaq snap losing streaks after jobless claims rise
- lululemon athletica (LULU) shares plunge despite earnings, revenue beat
- Banks may provide Elon Musk with new margin loans against Tesla stock - report
- DocuSign jumps after beating expectations for revenue and earnings
- Bath & Body Works gains as Dan Loeb's Third Point takes new stake, seeks board refreshment
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Dr. Snyder brings robust clinical development expertise from Two River and Merck & Co., Inc.
SOMERVILLE, Mass.--(BUSINESS WIRE)-- Generate Biomedicines, whose machine learning-powered generative biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, today announced that Alexandra Snyder, M.D. has been named Chief Medical Officer to oversee all clinical matters.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005362/en/
Alexandra Snyder, MD, Chief Medical Officer, Generate Biomedicines (Photo: Business Wire)
“We’re delighted Alex is joining the Generate Biomedicines team as we move our lead programs through IND enabling studies and toward the clinic,” said Mike Nally, Generate’s Chief Executive Officer. “Her impressive clinical experience, patient focus, and demonstrated leadership track record are crucial additions to our team as we pioneer the field of generative biology and pursue a broad portfolio of medicines.”
Dr. Snyder remarked, “Generate is revolutionizing drug development through a powerful new approach to creating protein therapeutics. I am thrilled to be part of such a talented team that will dramatically improve our ability to solve complex biological challenges and help improve the lives of patients with a broad range of medical conditions.”
Most recently, Dr. Snyder was a principal at the private equity firm Two River where she was responsible for setting the translational and clinical strategy and execution for Two River’s portfolio of novel biotech companies. Previously she was the Head of Translational Oncology at Merck. In this role, Dr. Snyder was responsible for conducting Merck-sponsored clinical trials across pipeline combination therapies at worldwide sites and the companion diagnostic strategy, biomarker programs and quantitative pharmacology for oncology clinical trials. Prior to joining industry, she practiced oncology at Memorial Sloan Kettering Cancer Center; she is currently a voluntary faculty member at Bellevue Hospital and New York University.
Dr. Snyder graduated summa cum laude from Princeton University with a degree in history and a minor in music. She received her medical education at Mount Sinai Medical School, graduated with the highest overall standing, and was an internal medicine resident at Mount Sinai Hospital and a medical oncology fellow at Memorial Sloan Kettering Cancer Center.
About Generative Biology
Generative biology represents a fundamental shift in therapeutic development that is driven by machine intelligence. This new approach leaves traditional trial and error methods of drug discovery behind and is ushering in a new era of programmable drug engineering. Rather than “discovering” what’s observable in the lab, Generate Biomedicines is creating therapeutic opportunities by identifying specific biological processes involved in disease that can be modulated with a wide range of protein modalities. The promise of generative biology goes beyond existing proteins found in nature and can generate entirely novel, de novo proteins that are purpose-built to address an existing or emerging therapeutic need. Generative biology will enable therapeutic achievements never before possible, creating entirely new ways to treat all types of diseases, drastically increasing the success rate, and reducing the time required for drug discovery.
About Generate Biomedicines
Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered multimodality generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. Through the seamless integration of computational and wet lab capabilities, Generate’s platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company’s platform represents a potentially fundamental shift in what’s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020. Learn more about Generate Biomedicines by visiting https://generatebiomedicines.com/ or following the company on Twitter and LinkedIn.
Source: Generate Biomedicines
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Another Sustainability Award for NTHU
- Calliditas to host fireside chat with its China commercial partner, Everest Medicines
- Russia: TotalEnergies Decides to Withdraw Its Directors From Novatek And Will No Longer Equity Account for Its Stake in Novatek and Record a 3.7 b$ Impairment in Q4
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!